Our operations are headquartered in Needham, MA. We currently occupy approximately 81,000 sq. ft. of fully equipped laboratory, manufacturing, research and office space and have approximately 100 employees in our 4 locations: Needham and Fall River, MA; Phillipsburg, NJ; and New Haven, CT.
Celldex is an innovative biotechnology company focused on the discovery, development and commercialization of targeted immunotherapies. Our core focus includes the use of tumor-specific targets, human monoclonal antibodies, and immune modulators as precision delivered therapeutic agents for the treatment of cancer, infectious and inflammatory diseases, which we call our Precision Targeted Immunotherapy approach. This includes the Antigen Presenting Cell Targeting Technology (APC Targeting Technology™) that utilizes proprietary human monoclonal antibodies to directly target specialized types of immune system cells known as antigen presenting cells or APCs - particularly dendritic cells. We are using this approach, along with complementary technologies, to build a substantial pipeline of clinical development candidates that will address significant gaps in the treatment of many cancers, as well specific infectious and inflammatory diseases.
Celldex has a highly experienced management team to implement our near- and long-term objectives of advancing our pre-clinical and clinical development programs through late-stage development, at which time we intend to identify optimal commercialization partners to market our products. Celldex will continue to explore synergistic partnerships to enhance our clinical, research and commercial opportunities.